Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized salbutamol vs epinephrine vs 5% hypertonic saline in infants with acute bronchiolitis
IRCT20201101049210N1Phase 3Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of salbutamol, epinephrine and sodium chloride in bronchiolitis (3 arms), sponsored by Golestan University of Medical Sciences. Primary endpoint: Severity of clinical symptoms. Started Nov 2020; status: completed.
02
Drugs
salbutamolepinephrinesodium chloride
03
Conditions
bronchiolitis
Beyond the preview
Go deeper on IRCT20201101049210N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201101049210N1.